Factors Influencing Adherence to Antipsychotic Medications in Women with Delusional
Disorder: A Narrative Review

Alexandre      González-Rodríguez; José   A.   Monreal; Mary      V. Seeman
Abstract

Background: Adherence to medication regimens is of great importance in psychiatry because drugs sometimes need to be taken for long durations in order to maintain health and function.
Objective: This study aimed to review influences on adherence to antipsychotic medications, the treatment of choice for the delusional disorder (DD), and to focus on adherence in women with DD.
Methods: This is a non-systematic narrative review of papers published since 2000 using PubMed and Google Scholar, focusing on women with DD and medication adherence.
Results: Several factors have been identified as exerting influence on adherence in women with persistent delusional symptoms who are treated with antipsychotics. Personality features, intensity of delusion, perception of adverse effects, and cognitive impairment are patient factors. Clinical time spent with the patient, clarity of communication, and regular drug monitoring are responsibilities of the health provider. Factors that neither patient nor clinician can control are the social determinants of health, such as poverty, easy access to healthcare, and cultural variables.
Conclusion: There has been little investigation of factors that influence adherence in the target population, e.g., women with DD. Preliminary results of this literature search indicate that solutions from outside the field of DD may apply to this population. Overall, a solid therapeutic alliance appears to be the best hedge against nonadherence.
Keywords: Delusional disorder, psychosis, women, medication adherence, compliance, psychiatric illness.
[1] 
Rea F, Mella M, Monzio CM, et al. Women discontinue antihypertensive drug therapy more than men. Evidence from an Italian population-based study. J Hypertens  2020; 38(1): 142-9.
[http://dx.doi.org/10.1097/HJH.0000000000002222] [PMID:  31464801] 
[2] 
Thompson A, Singh S, Birchwood M. Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis. Early Interv Psychiatry  2016; 10(4): 355-61.
[http://dx.doi.org/10.1111/eip.12244] [PMID:  25962446] 
[3] 
Cooper RE, Hanratty É, Morant N, Moncrieff J. Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLoS One  2019; 14(6), e0218711.
[http://dx.doi.org/10.1371/journal.pone.0218711] [PMID:  31220160] 
[4] 
Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther  2002; 24(8): 1347-57.
[http://dx.doi.org/10.1016/S0149-2918(02)80039-X] [PMID:  12240784] 
[5] 
Chen SL, Lee WL, Liang T, Liao IC. Factors associated with gender differences in medication adherence: A longitudinal study. J Adv Nurs  2014; 70(9): 2031-40.
[http://dx.doi.org/10.1111/jan.12361] [PMID:  24506542] 
[6] 
Biffi A, Rea F, Iannaccone T, Filippelli A, Mancia G, Corrao G. Sex differences in the adherence of antihypertensive drugs: A systematic review with meta-analyses. BMJ Open  2020; 10(7), e036418.
[http://dx.doi.org/10.1136/bmjopen-2019-036418] [PMID:  32641331] 
[7] 
Kulkarni KR, Arasappa R, Prasad MK, et al. Gender differences in persistent delusional disorder. Indian J Psychol Med  2017; 39(2): 216-7.
[http://dx.doi.org/10.4103/0253-7176.203123] [PMID:  28515568] 
[8] 
Settem VVJ, Karanadi H, Praharaj SK. Cognitive deficits, depressive symptoms, insight, and medication adherence in remitted patients with schizophrenia. Indian J Psychiatry  2019; 61(4): 335-41.
[http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_17_19] [PMID:  31391635] 
[9] 
Stentzel U, van den Berg N, Schulze LN, et al. Predictors of medication adherence among patients with severe psychiatric disorders: Findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry  2018; 18(1): 155.
[http://dx.doi.org/10.1186/s12888-018-1737-4] [PMID:  29843676] 
[10] 
de Portugal E, González N, Miriam V, Haro JM, Usall J, Cervilla JA. Gender differences in delusional disorder: Evidence from an outpatient sample. Psychiatry Res  2010; 177(1-2): 235-9.
[http://dx.doi.org/10.1016/j.psychres.2010.02.017] [PMID:  20334930] 
[11] 
Gu D, Shen C. Assessing the importance of factors associated with cost-related nonadherence to medication for older US medicare beneficiaries. Drugs Aging  2019; 36(12): 1111-21.
[http://dx.doi.org/10.1007/s40266-019-00715-3] [PMID:  31686403] 
[12] 
Lee S, Jiang L, Dowdy D, Hong YA, Ory MG. Attitudes, beliefs, and cost-related medication nonadherence among adults aged 65 or older with chronic diseases. Prev Chronic Dis  2018; 15, E148.
[http://dx.doi.org/10.5888/pcd15.180190] [PMID:  30522585] 
[13] 
Kang H, Lobo JM, Kim S, Sohn MW. Cost-related medication non-adherence among U.S. adults with diabetes. Diabetes Res Clin Pract  2018; 143: 24-33.
[http://dx.doi.org/10.1016/j.diabres.2018.06.016] [PMID:  29944967] 
[14] 
Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: A systematic review of the literature. Diabetes Educ  2016; 42(1): 34-71.
[http://dx.doi.org/10.1177/0145721715619038] [PMID:  26637240] 
[15] 
Choi YJ, Smaldone AM. Factors associated with medication engagement among older adults with diabetes: Systematic review and meta-analysis. Diabetes Educ  2018; 44(1): 15-30.
[http://dx.doi.org/10.1177/0145721717747880] [PMID:  29284354] 
[16] 
Williams J, Steers WN, Ettner SL, Mangione CM, Duru OK. Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes. Med Care  2013; 51(2): 193-8.
[http://dx.doi.org/10.1097/MLR.0b013e318270dc52] [PMID:  23032359] 
[17] 
Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt)  2014; 23(2): 112-9.
[http://dx.doi.org/10.1089/jwh.2012.3972] [PMID:  24206025] 
[18] 
Granger BB, Ekman I, Granger CB, et al. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail  2009; 11(11): 1092-8.
[http://dx.doi.org/10.1093/eurjhf/hfp142] [PMID:  19875409] 
[19] 
Thunander SL, Bingefors K. Women and men report different behaviours in, and reasons for medication non-adherence: A nationwide Swedish survey. Pharm Pract (Granada)  2012; 10(4): 207-21.
[http://dx.doi.org/10.4321/S1886-36552012000400005] [PMID:  24155839] 
[20] 
Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int  2015; 26(10): 2479-89.
[http://dx.doi.org/10.1007/s00198-015-3164-4] [PMID:  26018090] 
[21] 
Lai PS, Chua SS, Chew YY, Chan SP. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther  2011; 36(5): 557-67.
[http://dx.doi.org/10.1111/j.1365-2710.2010.01210.x] [PMID:  21916908] 
[22] 
Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: An analysis from real life data. J Hypertens  2014; 32(8): 1708-15.
[http://dx.doi.org/10.1097/HJH.0000000000000222] [PMID:  24842699] 
[23] 
Riley ED, Vittinghoff E, Koss CA, et al. Housing First: Unsuppressed viral load among women living with HIV in San Francisco. AIDS Behav  2019; 23(9): 2326-36.
[http://dx.doi.org/10.1007/s10461-019-02601-w] [PMID:  31324996] 
[24] 
McQuaid EL, Landier W. Cultural issues in medication adherence: Disparities and directions. J Gen Intern Med  2018; 33(2): 200-6.
[http://dx.doi.org/10.1007/s11606-017-4199-3] [PMID:  29204971] 
[25] 
Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer  2006; 42(14): 2271-6.
[http://dx.doi.org/10.1016/j.ejca.2006.03.004] [PMID:  16644208] 
[26] 
Sewitch MJ, Dobkin PL, Bernatsky S, et al. Medication non-adherence in women with fibromyalgia. Rheumatology (Oxford)  2004; 43(5): 648-54.
[http://dx.doi.org/10.1093/rheumatology/keh141] [PMID:  14983107] 
[27] 
Haskins CB, McDowell BD, Carnahan RM, et al. Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat  2019; 174(1): 197-208.
[http://dx.doi.org/10.1007/s10549-018-5050-1] [PMID:  30465157] 
[28] 
Haskins CB, Neuner JM, McDowell BD, et al. Effects of previous medication regimen factors and bipolar and psychotic disorders on breast cancer endocrine therapy adherence. Clin Breast Cancer  2020; 20(3): e261-80.
[http://dx.doi.org/10.1016/j.clbc.2019.09.005] [PMID:  32139273] 
[29] 
Haskins CB, McDowell BD, Carnahan RM, et al. Breast cancer endocrine therapy adherence in health professional shortage areas: Unique effects on patients with mental illness. J Psychosom Res  2021; 140, 110294.
[http://dx.doi.org/10.1016/j.jpsychores.2020.110294] [PMID:  33232903] 
[30] 
García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol  2016; 36(4): 355-71.
[http://dx.doi.org/10.1097/JCP.0000000000000523] [PMID:  27307187] 
[31] 
Forsman J, Taipale H, Masterman T, Tiihonen J, Tanskanen A. Adherence to psychotropic medication in completed suicide in Sweden 2006-2013: A forensic-toxicological matched case-control study. Eur J Clin Pharmacol  2019; 75(10): 1421-30.
[http://dx.doi.org/10.1007/s00228-019-02707-z] [PMID:  31218371] 
[32] 
Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry  2009; 70(Suppl. 4): 1-46.
[http://dx.doi.org/10.4088/JCP.7090su1cj] [PMID:  19686636] 
[33] 
Ritchie CW, Harrigan S, Mastwyk M, Macfarlane S, Cheesman N, Ames D. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: An open study of 3(1/2) years duration. Int J Geriatr Psychiatry  2010; 25(4): 411-8.
[http://dx.doi.org/10.1002/gps.2354] [PMID:  19946860] 
[34] 
Sapra M, Vahia IV, Reyes PN, Ramirez P, Cohen CI. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia. Schizophr Res  2008; 106(2-3): 348-55.
[http://dx.doi.org/10.1016/j.schres.2008.09.004] [PMID:  18851906] 
[35] 
Beck EM, Cavelti M, Wirtz M, Kossowsky J, Vauth R. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach. Psychiatry Res  2011; 187(1-2): 55-61.
[http://dx.doi.org/10.1016/j.psychres.2010.10.012] [PMID:  21074860] 
[36] 
Gonzalez J, Williams JW Jr, Noël PH, Lee S. Adherence to mental health treatment in a primary care clinic. J Am Board Fam Pract  2005; 18(2): 87-96.
[http://dx.doi.org/10.3122/jabfm.18.2.87] [PMID:  15798137] 
[37] 
Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: A systematic review and meta-analysis. BMC Psychiatry  2019; 19(1): 370.
[http://dx.doi.org/10.1186/s12888-019-2361-7] [PMID:  31775786] 
[38] 
Mousavi N, Norozpour M, Taherifar Z, Naserbakht M, Shabani A. Bipolar I disorder: A qualitative study of the viewpoints of the family members of patients on the nature of the disorder and pharmacological treatment non-adherence. BMC Psychiatry  2021; 21(1): 83.
[http://dx.doi.org/10.1186/s12888-020-03008-x] [PMID:  33557797] 
[39] 
Forma F, Green T, Kim S, Teigland C. Antipsychotic medication adherence and healthcare services utilization in two cohorts of patients with serious mental illness. Clinicoecon Outcomes Res  2020; 12: 123-32.
[http://dx.doi.org/10.2147/CEOR.S231000] [PMID:  32104024] 
[40] 
Lupattelli A, Spigset O, Björnsdóttir I, et al. Patterns and factors associated with low adherence to psychotropic medications during pregnancy--a cross-sectional, multinational web-based study. Depress Anxiety  2015; 32(6): 426-36.
[http://dx.doi.org/10.1002/da.22352] [PMID:  25703355] 
[41] 
González-Rodríguez A, Estrada F, Monreal JA, Palao D, Labad J. A systematic review of methods for the measurement of antipsychotic adherence in delusional disorder. J Clin Psychopharmacol  2018; 38(4): 412-4.
[http://dx.doi.org/10.1097/JCP.0000000000000893] [PMID:  29851708] 
[42] 
Tan C, Abdin E, Liang W, Poon LY, Poon NY, Verma S. Medication adherence in first-episode psychosis patients in Singapore. Early Interv Psychiatry  2019; 13(4): 780-8.
[http://dx.doi.org/10.1111/eip.12559] [PMID:  29521010] 
[43] 
Peralta V, Cuesta MJ. Delusional disorder and schizophrenia: A comparative study across multiple domains. Psychol Med  2016; 46(13): 2829-39.
[http://dx.doi.org/10.1017/S0033291716001501] [PMID:  27468631] 
[44] 
Chan KW, Hui LM, Wong HY, Lee HM, Chang WC, Chen YH. Medication adherence, knowledge about psychosis, and insight among patients with a schizophrenia-spectrum disorder. J Nerv Ment Dis  2014; 202(1): 25-9.
[http://dx.doi.org/10.1097/NMD.0000000000000068] [PMID:  24375208] 
[45] 
de Portugal E, González N, del Amo V, et al. Empirical redefinition of delusional disorder and its phenomenology: The DELIREMP study. Compr Psychiatry  2013; 54(3): 243-55.
[http://dx.doi.org/10.1016/j.comppsych.2012.08.002] [PMID:  23021895] 
[46] 
Kampman O, Laippala P, Väänänen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res  2002; 110(1): 39-48.
[http://dx.doi.org/10.1016/S0165-1781(02)00030-6] [PMID:  12007592] 
[47] 
Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull  2006; 32(4): 644-54.
[http://dx.doi.org/10.1093/schbul/sbl010] [PMID:  16887890] 
[48] 
Steger KA, Cassidy C, Rabinovitch M, Joober R, Malla A. Impact of symptom resolution on medication adherence in first episode psychosis. Psychiatry Res  2012; 196(1): 45-51.
[http://dx.doi.org/10.1016/j.psychres.2011.10.015] [PMID:  22377571] 
[49] 
Wustmann T, Pillmann F, Marneros A. Gender-related features of persistent delusional disorders. Eur Arch Psychiatry Clin Neurosci  2011; 261(1): 29-36.
[http://dx.doi.org/10.1007/s00406-010-0130-1] [PMID:  20700601] 
[50] 
González-Rodríguez A, Molina-Andreu O, Penadés R, Bernardo M, Catalán R. Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. Int Clin Psychopharmacol  2014; 29(3): 177-80.
[http://dx.doi.org/10.1097/YIC.0000000000000020] [PMID:  24681811] 
[51] 
Liraud F, Verdoux H. Association between temperamental characteristics and medication adherence in subjects presenting with psychotic or mood disorders. Psychiatry Res  2001; 102(1): 91-5.
[http://dx.doi.org/10.1016/S0165-1781(01)00240-2] [PMID:  11368844] 
[52] 
Seeman MV. Antipsychotics and physical attractiveness. Clin Schizophr Relat Psychoses  2011; 5(3): 142-6.
[http://dx.doi.org/10.3371/CSRP.5.3.4] [PMID:  21983498] 
[53] 
Seeman MV. Antipsychotic-induced somnolence in mothers with schizophrenia. Psychiatr Q  2012; 83(1): 83-9.
[http://dx.doi.org/10.1007/s11126-011-9185-z] [PMID:  21739299] 
[54] 
Seeman MV. Antipsychotic-induced amenorrhea. J Ment Health  2011; 20(5): 484-91.
[http://dx.doi.org/10.3109/09638237.2011.586741] [PMID:  21942684] 
[55] 
Seeman MV. Prescription drugs parents take: Consequences for children. Scientific J Depress Anxiety  2017; 1(1): 8-13.
[56] 
Seeman MV. Assessing the effects of antipsychotics on parenting. Womens Health Bull  2018; 5(1), e13409.
[http://dx.doi.org/10.5812/whb.13409] 
[57] 
Seeman MV. Antipsychotics during pregnancy: Pros and cons.
  Open J Gynecol Obstet Res 1: 58-64.. 
[http://dx.doi.org/10.36811/ojgor.2019.110010] 
[58] 
Souaiby L, Kazour F, Zoghbi M, Bou Khalil R, Richa S. Sexual dysfunction in patients with schizophrenia and schizoaffective disorder and its association with adherence to antipsychotic medication. J Ment Health  2020; 29(6): 623-30.
[http://dx.doi.org/10.1080/09638237.2019.1581333] [PMID:  30862199] 
[59] 
Tosato S, Albert U, Tomassi S, et al. A Systematized review of atypical antipsychotics in pregnant women: Balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry  2017; 78(5): e477-89.
[http://dx.doi.org/10.4088/JCP.15r10483] [PMID:  28297592] 
[60] 
Yeisen RAH, Bjornestad J, Joa I, Johannessen JO, Opjordsmoen S. Experiences of antipsychotic use in patients with early psychosis: A two-year follow-up study. BMC Psychiatry  2017; 17(1): 299.
[http://dx.doi.org/10.1186/s12888-017-1425-9] [PMID:  28830453] 
[61] 
McCabe R, Healey PG, Priebe S, et al. Shared understanding in psychiatrist-patient communication: Association with treatment adherence in schizophrenia. Patient Educ Couns  2013; 93(1): 73-9.
[http://dx.doi.org/10.1016/j.pec.2013.05.015] [PMID:  23856552] 
[62] 
Opjordsmoen S, Friis S, Melle I, et al. A 2-year follow-up of involuntary admission’s influence upon adherence and outcome in first-episode psychosis. Acta Psychiatr Scand  2010; 121(5): 371-6.
[http://dx.doi.org/10.1111/j.1600-0447.2009.01536.x] [PMID:  20085554] 
[63] 
González-Rodríguez A, Catalán R, Penadés R, Ruiz V, Torra M, Bernardo M. Antipsychotic response in delusional disorder and schizophrenia: A prospective cohort study. Actas Esp Psiquiatr  2016; 44(4): 125-35.
[PMID:  27388104] 
[64] 
González-Rodríguez A, Molina-Andreu O, Imaz Gurrutxaga ML, Catalán Campos R, Arroyo MB. A descriptive retrospective study of the treatment and outpatient service use in a clinical group of delusional disorder patients. Rev Psiquiatr Salud Ment  2014; 7(2): 64-71.
[http://dx.doi.org/10.1016/j.rpsmen.2014.02.004] [PMID:  23490496] 
[65] 
Grover S, Biswas P, Avasthi A. Delusional disorder: Study from North India. Psychiatry Clin Neurosci  2007; 61(5): 462-70.
[http://dx.doi.org/10.1111/j.1440-1819.2007.01694.x] [PMID:  17875023] 
[66] 
Citrome L. Long-acting injectable antipsychotics: What, when, and how - Addendum. CNS Spectr  2021; 26(2): 184.
[http://dx.doi.org/10.1017/S1092852921000456] [PMID:  33928884] 
[67] 
Tinland A, Zemmour K, Auquier P, et al. French Housing First Study Group. Homeless women with schizophrenia reported lower adherence to their medication than men: Results from the French Housing First experience. Soc Psychiatry Psychiatr Epidemiol  2017; 52(9): 1113-22.
[http://dx.doi.org/10.1007/s00127-017-1411-z] [PMID:  28656452] 
[68] 
Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophr Bull  2004; 30(2): 255-64.
[http://dx.doi.org/10.1093/oxfordjournals.schbul.a007076] [PMID:  15279044] 
[69] 
Sajatovic M, Mbwambo J, Lema I, et al. Correlates of poor medication adherence in chronic psychotic disorders. BJPsych Open  2021; 7(1), E23.
[http://dx.doi.org/10.1192/bjo.2020.141] 
[70] 
Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A. The influence of perceived social support on medication adherence in first-episode psychosis. Can J Psychiatry  2013; 58(1): 59-65.
[http://dx.doi.org/10.1177/070674371305800111] [PMID:  23327758] 
[71] 
Bauldry S, Szaflarski M. Immigrant-based disparities in mental health care utilization. Socius  2017; 3: 1-14.
[http://dx.doi.org/10.1177/2378023116685718] [PMID:  28845455] 
[72] 
Markova V, Sandal GM. Lay explanatory models of depression and preferred coping strategies among Somali refugees in Norway. A mixed-method study. Front Psychol  2016; 7: 1435.
[http://dx.doi.org/10.3389/fpsyg.2016.01435] [PMID:  27713719] 
[73] 
Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade. Eur Psychiatry  2012; 27(1): 9-18.
[http://dx.doi.org/10.1016/j.eurpsy.2011.02.005] [PMID:  21561742] 
[74] 
Muñoz-Negro JE, Cervilla JA. The comprehensive treatment of delusional disorder. Rev Psiquiatr Salud Ment  2017; 10(4): 221-3.
[http://dx.doi.org/10.1016/j.rpsm.2017.03.003] [PMID:  28476504] 
[75] 
Arango C, Baeza I, Bernardo M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment  2019; 12(2): 92-105.
[http://dx.doi.org/10.1016/j.rpsmen.2018.03.004] [PMID:  29954707] 
[76] 
Uko-Ekpenyong G. Improving medication adherence with orally disintegrating tablets. Nursing  2006; 36(9): 20-1.
[http://dx.doi.org/10.1097/00152193-200609000-00012] [PMID:  16951598] 
[77] 
Arranz B, San L, Dueñas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol  2007; 22(1): 11-5.
[http://dx.doi.org/10.1002/hup.819] [PMID:  17191265] 
[78] 
Medic G, Higashi K, Littlewood KJ, Diez T, Granström O, Kahn RS. Dosing frequency and adherence in chronic psychiatric disease: Systematic review and meta-analysis. Neuropsychiatr Dis Treat  2013; 9: 119-31.
[http://dx.doi.org/10.2147/NDT.S39303] [PMID:  23355782] 
[79] 
Wesley EW, Patel I, Kadra-Scalzo G, et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. Schizophr Res  2021; 232: 68-76.
[http://dx.doi.org/10.1016/j.schres.2021.05.006] [PMID:  34022618] 
[80] 
Kane JM. Lessening the side effect burden to improve adherence
  among individuals with schizophrenia. J Clin Psychiatry 2021;
  82(2): IC20018BR1C.. 
[http://dx.doi.org/10.4088/JCP.IC20018BR1C] 
[81] 
Seeman MV, González-Rodríguez A. Use of psychotropic medication in women with psychotic disorders at menopause and beyond. Curr Opin Psychiatry  2018; 31(3): 183-92.
[http://dx.doi.org/10.1097/YCO.0000000000000410] [PMID:  29528895] 
[82] 
Seeman MV. Secondary effects of antipsychotics: Women at greater risk than men. Schizophr Bull  2009; 35(5): 937-48.
[http://dx.doi.org/10.1093/schbul/sbn023] [PMID:  18400811] 
[83] 
Lisoway AJ, Chen CC, Zai CC, Tiwari AK, Kennedy JL. Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. Schizophr Res  2021; 232: 112-24.
[http://dx.doi.org/10.1016/j.schres.2021.05.010] [PMID:  34049235] 
[84] 
van Westrhenen R, van Schaik RHN, van Gelder T, et al. Policy and practice review: A first guideline on the use of pharmacogenetics in clinical psychiatric practice. Front Pharmacol  2021; 12, 640032.
[http://dx.doi.org/10.3389/fphar.2021.640032] [PMID:  33995044] 
[85] 
González-Rodríguez A, Seeman MV, Álvarez A, et al. Care for women with delusional disorder: Towards a specialized approach. Women  2021; 1(1): 46-59.
[http://dx.doi.org/10.3390/women1010004] 
[86] 
González-Rodríguez A, Alvarez A, Guàrdia A, et al. Psychiatric partial hospitalization programs: Following world health organization guidelines with a special focus on women with delusional disorder. Women  2021; 1(2): 80-96.
[http://dx.doi.org/10.3390/women1020008] 
[87] 
Hartung D, Low A, Jindai K, et al. Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: A systematic review. Psychosomatics  2017; 58(2): 101-12.
[http://dx.doi.org/10.1016/j.psym.2016.09.009] [PMID:  28139249] 
[88] 
Marvin SE, Miklowitz DJ, O’Brien MP, Cannon TD. Family-focused therapy for individuals at clinical high risk for psychosis: Treatment fidelity within a multisite randomized trial. Early Interv Psychiatry  2016; 10(2): 137-43.
[http://dx.doi.org/10.1111/eip.12144] [PMID:  24725329] 
[89] 
Sin J, Gillard S, Spain D, Cornelius V, Chen T, Henderson C. Effectiveness of psychoeducational interventions for family carers of people with psychosis: A systematic review and meta-analysis. Clin Psychol Rev  2017; 56: 13-24.
[http://dx.doi.org/10.1016/j.cpr.2017.05.002] [PMID:  28578249] 
[90] 
Priebe S, Burton A, Ashby D, et al. Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT). BMC Psychiatry  2009; 9(1): 61.
[http://dx.doi.org/10.1186/1471-244X-9-61] [PMID:  19785727] 
[91] 
Burns T. Is it acceptable for people to be paid to adhere to medication? Yes. BMJ  2007; 335(7613): 232.
[http://dx.doi.org/10.1136/bmj.39286.399514.BE] [PMID:  17673764] 
[92] 
Dennis R, Christian R, Palokas M. Effectiveness of financial incentives for long-acting injectable antipsychotic adherence in patients with psychotic and bipolar disorders: A systematic review protocol. JBI Database Syst Rev Implement Reports  2019; 17(1): 43-8.
[http://dx.doi.org/10.11124/JBISRIR-2017-003926] [PMID:  30629042] 
[93] 
Highton-Williamson E, Barnicot K, Kareem T, Priebe S. Offering financial incentives to increase adherence to antipsychotic medication: The clinician experience. J Clin Psychopharmacol  2015; 35(2): 120-7.
[http://dx.doi.org/10.1097/JCP.0000000000000276] [PMID:  25692797] 
[94] 
Noordraven EL, Audier CH, Staring AB, et al. Money for medication: A randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders. BMC Psychiatry  2014; 14(1): 343.
[http://dx.doi.org/10.1186/s12888-014-0343-3] [PMID:  25438877] 
[95] 
Shaw J. Is it acceptable for people to be paid to adhere to medication? No. BMJ  2007; 335(7613): 233.
[http://dx.doi.org/10.1136/bmj.39286.422639.BE] [PMID:  17673765] 
[96] 
Beebe LH, Smith K, Phillips C. Effect of a telephone intervention on measures of psychiatric and nonpsychiatric medication adherence in outpatients with schizophrenia spectrum disorders. J Psychosoc Nurs Ment Health Serv  2017; 55(1): 29-36.
[http://dx.doi.org/10.3928/02793695-20170119-04] [PMID:  28135389] 
[97] 
Gowda GS, Perumalla BR, Enara A, et al. Video based intervention to improve compliance with prescribed drug regimen. Asian J Psychiatr  2019; 43: 99-100.
[http://dx.doi.org/10.1016/j.ajp.2019.05.020] [PMID:  31121537] 
[98] 
Gilden J, Staring AB, der Gaag M, Mulder CL. Does treatment adherence therapy reduce expense of healthcare use in patients with psychotic disorders? Cost-minimization analysis in a randomized controlled trial. Schizophr Res  2011; 133(1-3): 47-53.
[http://dx.doi.org/10.1016/j.schres.2011.09.025] [PMID:  21999905] 
[99] 
Franke I, Thier S, Riecher-Rössler A. Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders. Neuropsychiatrie (Deisenhof)  2016; 30(4): 191-7.
[http://dx.doi.org/10.1007/s40211-016-0202-1] [PMID:  27822730] 
[100] 
Kreyenbuhl J, Record EJ, Himelhoch S, et al. Development and feasibility testing of a smartphone intervention to improve adherence to antipsychotic medications. Clin Schizophr Relat Psychoses  2019; 12(4): 152-67.
[http://dx.doi.org/10.3371/CSRP.KRRE.070816] [PMID:  27454213] 
[101] 
Agara AJ, Onibi OE. Effects of group psychoeducation (GPE) on compliance with scheduled clinic appointments in a neuro-psychiatric hospital in southwest Nigeria: A Randomised Control Trial (RCT). Ann Acad Med Singapore  2007; 36(4): 272-5.
[PMID:  17483857] 
[102] 
Meehan AJ. From conversion to coercion: The police role in medication compliance. Psychiatr Q  1995; 66(2): 163-84.
[http://dx.doi.org/10.1007/BF02238862] [PMID:  7652098] 
[103] 
Jäger M, Rössler W. Informeller zwang zur verbesserung der behandlungsbereitschaft psychiatrischer patienten. Neuropsychiatrie (Deisenhof)  2009; 23(4): 206-15.
[PMID:  19909692] 
[104] 
Huddy V, Reeder C, Kontis D, Wykes T, Stahl D. The effect of working alliance on adherence and outcome in cognitive remediation therapy. J Nerv Ment Dis  2012; 200(7): 614-9.
[http://dx.doi.org/10.1097/NMD.0b013e31825bfc31] [PMID:  22759940] 
[105] 
Papageorgiou A, Loke YK, Fromage M. Communication skills training for mental health professionals working with people with severe mental illness. Cochrane Database Syst Rev  2017; 6(6), CD010006.
[http://dx.doi.org/10.1002/14651858.CD010006.pub2] [PMID:  28613384] 
[106] 
Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: A meta-analysis. Schizophr Res  2007; 96(1-3): 232-45.
[http://dx.doi.org/10.1016/j.schres.2007.07.022] [PMID:  17826034] 
[107] 
Lowen C, Hodgekins J, Pugh K, et al. Measuring adherence in social recovery therapy with people with first episode psychosis. Behav Cogn Psychother  2020; 48(1): 82-90.
[http://dx.doi.org/10.1017/S1352465819000432] [PMID:  31379311] 
[108] 
Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res  2015; 225(1-2): 14-30.
[http://dx.doi.org/10.1016/j.psychres.2014.11.002] [PMID:  25466227] 
[109] 
Fujikawa M, Togo T, Yoshimi A, et al. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry  2008; 32(3): 755-60.
[http://dx.doi.org/10.1016/j.pnpbp.2007.12.002] [PMID:  18226436] 
[110] 
Seeman MV, Seeman N. The meaning of antipsychotic medication to patients with schizophrenia. J Psychiatr Pract  2012; 18(5): 338-48.
[http://dx.doi.org/10.1097/01.pra.0000419818.60505.95] [PMID:  22995961] 
[111] 
González-Rodríguez A, Seeman MV. Addressing delusions in women and men with delusional disorder: Key points for clinical management. Int J Environ Res Public Health  2020; 17(12): 4583.
[http://dx.doi.org/10.3390/ijerph17124583] [PMID:  32630566] 
[112] 
Cusanno BR, Dean M, Silva VT. “I’m worth saving”: Making sense of medication taking in a care coordination organization. Health Commun  2021; 1-14.
[http://dx.doi.org/10.1080/10410236.2021.1920713] [PMID:  33947311] 
[113] 
Ashoorian DM, Davidson RM. Shared decision making for psychiatric medication management: A summary of its uptake, barriers and facilitators. Int J Clin Pharm  2021; 43(3): 759-63.
[http://dx.doi.org/10.1007/s11096-021-01240-3] [PMID:  33515136] 
[114] 
Brain C, Allerby K, Sameby B, et al. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish COAST-study. Eur Neuropsychopharmacol  2013; 23(12): 1754-62.
[http://dx.doi.org/10.1016/j.euroneuro.2013.09.001] [PMID:  24091164] 
[115] 
Moschny N, Hefner G, Grohmann R, et al. Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-Influence of smoking behavior and inflammation on pharmacokinetics. Pharmaceuticals (Basel)  2021; 14(6): 514.
[http://dx.doi.org/10.3390/ph14060514] [PMID:  34071813] 
Cite As
Current Pharmaceutical Design

Factors Influencing Adherence to Antipsychotic Medications in Women with Delusional Disorder: A Narrative Review

Abstract
